{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:13:09Z","timestamp":1790485989864,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.1097\/qad.0b013e328352d135","type":"journal-article","created":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T04:18:19Z","timestamp":1330575499000},"page":"1151-1159","source":"Crossref","is-referenced-by-count":117,"title":["Safety of tenofovir use during pregnancy"],"prefix":"10.1097","volume":"26","author":[{"given":"George K.","family":"Siberry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George R.","family":"Seage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise L.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Hazra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Griner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Tassiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Kacanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne M.","family":"Mofenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"DiMeglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Heather","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-11-20210130","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00042560-200203010-00001","article-title":"Fetal and maternal outcome after administration of tenofovir to gravid Rhesus monkeys (Macaca mulatta).","volume":"29","author":"Tarantal","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-11-20210130","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1128\/AAC.48.5.1469-1487.2004","article-title":"Biological effects of short-term or prolonged administration of 9-2-(phosphonomethoxy) propyl.adenine (tenofovir) to newborn and infant rhesus macaques.","volume":"48","author":"Van Rompay","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-11-20210130","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics, biological and virological effects.","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-11-20210130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1468-1293.2009.00709.x","article-title":"Tenofovir disproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine.","volume":"10","author":"Foster","year":"2009","journal-title":"HIV Med"},{"key":"R7-11-20210130","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/clpt.2008.201","article-title":"ANRS 12109Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109).","volume":"85","author":"Hirt","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"R8-11-20210130","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1345\/aph.1L083","article-title":"Adverse effects of tenofovir use in HIV-infected pregnant women and their infants.","volume":"42","author":"Nurutdinova","year":"2008","journal-title":"Ann Pharmacother"},{"key":"R9-11-20210130","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s10461-010-9705-0","article-title":"Substance use in HIV-infected women during pregnancy: self-report versus meconium analysis.","volume":"14","author":"Tassiopoulos","year":"2010","journal-title":"AIDS Behav"},{"key":"R10-11-20210130","first-page":"1","article-title":"CDC growth charts: United States.","volume":"314","author":"Kuczmarski","year":"2000","journal-title":"Adv Data"},{"key":"R11-11-20210130","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/sj.ejcn.1602667","article-title":"Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart.","volume":"61","author":"Fenton","year":"2007","journal-title":"Eur J Clin Nutr"},{"key":"R12-11-20210130","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2431-3-13","article-title":"A new growth chart for preterm babies: Babson and Bendas chart updated with recent data and a new format.","volume":"3","author":"Fenton","year":"2003","journal-title":"BMC Pediatr"},{"key":"R13-11-20210130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/507645","article-title":"Women and Infants Transmission StudyEffect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: an analysis of the women and infants transmission study.","volume":"194","author":"Pacheco","year":"2006","journal-title":"J Infect Dis"},{"key":"R14-11-20210130","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(99)07219-0","article-title":"Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.","volume":"354","author":"Blanche","year":"1999","journal-title":"Lancet"},{"key":"R15-11-20210130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(02)07717-6","article-title":"Risk of early febrile seizures with perinatal exposure to nucleoside analogues.","volume":"359","author":"Landreau-Mascaro","year":"2002","journal-title":"Lancet"},{"key":"R16-11-20210130","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e328311d18b","article-title":"ANRS-Enquete Perinatale FrancaiseIncidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors.","volume":"22","author":"Benhammou","year":"2008","journal-title":"AIDS"},{"key":"R17-11-20210130","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1097\/00002030-200309260-00006","article-title":"Enquete Perinatale Francaise Study GroupPerinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants.","volume":"17","author":"Le Chenadec","year":"2003","journal-title":"AIDS"},{"key":"R18-11-20210130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.taap.2003.11.034","article-title":"Perinatal genotoxicity and carcinogenicity of antiretroviral nucleoside analog drugs.","volume":"199","author":"Poirier","year":"2004","journal-title":"Toxicol Appl Pharmacol"},{"key":"R19-11-20210130","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/jac\/dkp316","article-title":"Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms.","volume":"64","author":"Maagaard","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"R20-11-20210130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0166-3542(03)00005-6","article-title":"Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys, and woodchucks.","volume":"58","author":"Biesecker","year":"2003","journal-title":"Antiviral Res"},{"key":"R21-11-20210130","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/656417","article-title":"ASSERT Study GroupComparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.","volume":"51","author":"Stellbrink","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R22-11-20210130","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1093\/infdis\/jir188","article-title":"Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202.","volume":"203","author":"McComsey","year":"2011","journal-title":"J Infect Dis"},{"key":"R23-11-20210130","doi-asserted-by":"crossref","first-page":"e846","DOI":"10.1542\/peds.2005-0975","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.","volume":"116","author":"Hazra","year":"2005","journal-title":"Pediatrics"},{"key":"R24-11-20210130","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1542\/peds.2005-2525","article-title":"Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children.","volume":"118","author":"Gafni","year":"2006","journal-title":"Pediatrics"},{"key":"R25-11-20210130","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/QAI.0b013e3181ffa4f5","article-title":"Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana.","volume":"56","author":"Powis","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-11-20210130","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/QAD.0b013e32832be0df","article-title":"ANRS French Perinatal CohortNo relation between in-utero exposure to HAART and intrauterine growth retardation.","volume":"23","author":"Briand","year":"2009","journal-title":"AIDS"},{"key":"R27-11-20210130","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa991159","article-title":"Antiretroviral therapy during pregnancy and the risk of an adverse outcome.","volume":"346","author":"Tuomala","year":"2002","journal-title":"N Engl J Med"},{"key":"R28-11-20210130","doi-asserted-by":"crossref","first-page":"e900","DOI":"10.1542\/peds.2006-1123","article-title":"Pediatric Spectrum of HIV Disease ConsortiumDeclines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric spectrum of HIV disease, 1989-2004.","volume":"119","author":"Schulte","year":"2007","journal-title":"Pediatrics"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201206010-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:42:50Z","timestamp":1786048970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-201206010-00011"}},"subtitle":["early growth outcomes in HIV-exposed uninfected infants"],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e328352d135","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}